文献速递慢阻肺

慢阻肺患者真实世界步态数字化测量的欧洲研究

How do people with COPD walk? A European study on digitally measured real-world gait.
PubMed 文献 · Eur Respir J · 2025-07-24

该研究纳入7个欧洲中心549例慢阻肺患者和19名健康老年人,佩戴单 wearable 设备连续1周,计算15项数字化移动结局(DMO)。结果显示步态DMO呈正态分布且个体间变异大,步行速度和步频随疾病严重程度增加而降低,且与健康同龄人相比存在显著差异。

要点

  • 慢阻肺患者步态参数呈正态分布,个体间变异大
  • 步行速度和步频随GOLD分级升高而降低
  • 与健康老年人相比,慢阻肺患者步行速度和步频显著降低

核心结论

  • 慢阻肺患者步态DMO呈正态分布,并随疾病进展而恶化。
  • 与健康同龄人相比,步行速度和步频DMO显著改变。

研究设计与样本

  • 多中心观察性研究,纳入7个欧洲中心的549例慢阻肺患者和19名健康老年人。
  • 使用单 wearable 设备(Axivity AX6或DynaPort MoveMonitor MM+)连续佩戴1周,识别步行片段并计算15项DMO,汇总至周水平。

主要发现

  • 所有步态DMO呈正态分布,个体间存在变异,例如平均±标准差步行速度为0.83±0.12 m·s-1,范围0.48至1.20 m·s-1。
  • 步行速度和步频DMO随疾病严重程度增加而降低,例如GOLD 1至4级平均±标准差步行速度分别为0.88±0.11、0.85±0.12、0.80±0.12和0.78±0.14 m·s-1,p<0.001;GOLD A、B、E级平均±标准差步频分别为93±6、91±6和89±7 steps·min-1,p=0.013。
  • 步幅长度和持续时间在不同COPD严重程度间存在差异。
  • 步行速度和步频的逐次变异仅在不同呼吸困难严重程度间存在差异。
  • 与19名健康老年人(47%女性,平均年龄71±6岁)相比,慢阻肺患者步行速度和步频存在差异,例如平均±标准差步行速度0.83±0.12 versus 0.90±0.12 m·s-1,p=0.041。

临床怎么用

  • 临床可借助可穿戴设备连续监测慢阻肺患者真实世界步态,评估移动能力。
  • 步行速度和步频可作为反映疾病严重程度的潜在数字化指标。

局限性

  • 健康对照组样本量较小(19例),且为方便样本。
  • 研究为观察性设计,无法推断因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The amount of walking that people with COPD do is reduced. However, data on their manner of walking (i.e. gait) are still lacking. We characterised real-world gait in COPD by assessing levels and distributions of gait parameters, and comparing them across COPD severity and with healthy peers. METHODS: 549 people with COPD from seven European sites and 19 healthy older adults wore single wearable devices (either Axivity AX6 or DynaPort MoveMonitor MM+) continuously for 1 week, from which we identified walking bouts, calculated 15 digital mobility outcomes (DMOs) aggregated at the weekly level, and compared them across COPD severity levels and with healthy peers. RESULTS: Of the participants with COPD, 37% were female with a mean±sd age of 68±8 years and a post-bronchodilator forced expiratory volume in 1 s of 54±20% predicted. All gait DMOs were normally distributed and exhibited variability between participants (e.g. mean±sd walking speed of 0.83±0.12 m·s-1, ranging from 0.48 to 1.20 m·s-1). Walking speed and cadence DMOs were lower with increasing disease severity (e.g. mean±sd walking speed of 0.88±0.11, 0.85±0.12, 0.80±0.12 and 0.78±0.14 m·s-1 across Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades 1 to 4, p<0.001; mean±sd cadence of 93±6, 91±6 and 89±7 steps·min-1 across GOLD A, B and E, p=0.013). Stride length and duration varied across COPD severity levels. Walking speed and cadence bout-to-bout variability only varied across dyspnoea severity levels. In a secondary analysis, we compared DMO data from people with COPD to a convenience sample of 19 healthy older adults (47% women, mean age 71±6 years) and found that walking speed and cadence varied between participants with COPD and healthy adults (e.g. mean±sd walking speed 0.83±0.12 versus 0.90±0.12 m·s-1, p=0.041). CONCLUSION: In people with COPD, gait DMOs are normally distributed and worsen as disease advances. Moreover, walking speed and cadence DMOs are significantly altered when compared to healthy peers. Further research should elucidate which DMOs can be improved with treatments to enhance mobility and reduce adverse events.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Delgado-Ortiz L, Buekers J, Chynkiamis N, et al. How do people with COPD walk? A European study on digitally measured real-world gait. Eur Respir J. 2025. PMID: 40404212. doi:10.1183/13993003.02303-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。